C-Bridge Capital is a healthcare-focused private equity firm established in 2013 and headquartered in Shanghai, China. They primarily focus on investing within the healthcare sector, targeting high-growth opportunities in bio-technology, pharmaceuticals, mobile health, medical devices, medical equipment, diagnostics, and drug development sectors. C-Bridge Capital aims to build a bridge to connect and bring international healthcare advances to China, especially through their investments. They provide not only capital but also strategic support to their portfolio companies to enhance their valuation and position them for success in China's fast-growing healthcare market. With a deep understanding of the healthcare policy environment and market dynamics in China, they strive to identify companies that can benefit from the rapidly increasing demand for healthcare services and technologies in the region. Their team consists of professionals with extensive experience in healthcare, finance, and management, which allows them to add value in areas such as operations, regulatory affairs, and market access strategies. C-Bridge Capital looks to back innovative products and technologies that address unmet medical needs and can be scaled in the Chinese market and beyond. By leveraging their local expertise and international reach, they are committed to fostering growth and innovation in the global healthcare industry, ultimately improving patient care and outcomes.